Know Cancer

forgot password

The Influence of Selenium on Biomarkers of Prostate Cancer Risk

20 Years
79 Years
Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

The Influence of Selenium on Biomarkers of Prostate Cancer Risk

We will conduct a double-blind, randomized, placebo-controlled clinical study of selenium
supplementation in the form of L-selenomethionine (SM)(200 µg/day) and selenium-enriched
yeast (SY) (200 µg/day and 285 µg/day) for 12 months; the 285 µg/day SY is selected to
deliver an equivalent selenium as in 200 µg/day SM to healthy men. Some time during the 12
months study period, all groups will take the placebo pill for at least 3 months. The
subjects will compose of African Americans, Hispanics, and white Americans in different age
groups defined as follows: Young adult (20-39 year old), Matured adult (40-59 year old), Old
adult (60-79 year old). The Young adult group will serve as a reference group and will be
used to validate our previous results. The variability of SM in SY that will be used here is
less than 3% and it accounts for 70.5% of the SM content in SY.

Inclusion Criteria:

- No history or evidence of diabetes

- Male between the ages of 20-79

- PSA levels ≤ 4.0 ng/mL

- Not taking >50 µg/day selenium as a dietary supplement including multi- vitamins

- Non-smoker

- No concurrently participating or have participated in any other clinical trial within
at least 30 days of registration

- Health male

Exclusion Criteria:

- Evidence of prostate cancer

- Evidence of liver or kidney disease

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Outcome Measure:

PSA levels

Outcome Time Frame:

18 months

Safety Issue:


Principal Investigator

Karam El-Bayoumy, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Penn State College of Medicine


United States: Institutional Review Board

Study ID:

PSHCI 08-012



Start Date:

May 2008

Completion Date:

May 2013

Related Keywords:

  • Prostate Cancer
  • prostate cancer
  • PSA
  • testosterone
  • Prostatic Neoplasms



Penn State Milton Hershey Medical CenterHershey, Pennsylvania  17033